New hope for hard-to-treat esophageal cancer?

NCT ID NCT05022654

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread. The goal is to see if the combo can shrink tumors and control the disease. About 22 adults who have already tried standard treatments are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anyang Cancer Hospital of Henan Province

    Anyang, Henan, China

  • Beijing Cancer Hostital

    Beijing, Beijing Municipality, 100142, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China